2021
DOI: 10.1111/jdv.17144
|View full text |Cite
|
Sign up to set email alerts
|

Alemtuzumab, total skin electron beam, and non‐myeloablative allogeneic haematopoietic stem‐cell transplantation in advanced sezary syndrome: a retrospective cohort study

Abstract: To the Editor Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease associated with arthritis of inflammatory aetiology such as rheumatoid arthritis. 1 To date, the association between AD and non-inflammatory arthritis remains unknown. This study sought to determine whether AD is associated with increased risk of osteoarthritis (OA) in adults from the 1999-2006 National Health and Nutrition Examination Survey (NHANES), a national representative database of health and

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 7 publications
0
1
0
Order By: Relevance
“…[4] Sequencing therapies to achieve the best response preallogeneic stem cell transplantation is as important as considering the potential modifications on immune system modulation that might impact the transplant outcomes. [5][6][7][8] Assessing tumor burden by direct skin examination, PET-CT, and flow cytometry are the classic established methods to evaluate the disease response to therapies. [9] Still, new drugs such as anti-CCR4 and CD30 monoclonal antibodies require in-depth immunotypic analysis of normal and neoplastic populations to understand our patients' evolution better.…”
Section: Introductionmentioning
confidence: 99%
“…[4] Sequencing therapies to achieve the best response preallogeneic stem cell transplantation is as important as considering the potential modifications on immune system modulation that might impact the transplant outcomes. [5][6][7][8] Assessing tumor burden by direct skin examination, PET-CT, and flow cytometry are the classic established methods to evaluate the disease response to therapies. [9] Still, new drugs such as anti-CCR4 and CD30 monoclonal antibodies require in-depth immunotypic analysis of normal and neoplastic populations to understand our patients' evolution better.…”
Section: Introductionmentioning
confidence: 99%